Actavis launches dorzolamide eye drops

Actavis has announced the launch of a new dorzolamide eye drops solution product in the UK.

The latest addition to the pharmacy supplier's portfolio is a monotherapy for patients with heart conditions or hypertension who have proven unresponsive to beta blockers, or are unable to utilise the latter treatment due to contraindication.

A spokesperson for the company stated that it is also intended for use in the treatment of intraocular pressure, reports Chemist and Druggist.

This gives it potential applications among patients suffering from eye conditions such as ocular hypertension, open-angle glaucoma and pseudo-exfoliative glaucoma.

Last month, Actavis released Olanzapine tablets – a new generic treatment of schizophrenia and bipolar disorder – in four European nations following the expiry of the patent on Zyprexa, the Lilly-developed branded product on which it is based.

Patents for the therapy in the majority of other EU nations will expire in September 2011, enabling Actavis to conduct additional launches.